Century Therapeutics, Inc. (NASDAQ:IPSC) is one of the 10 Fastest Growing Tech Penny Stocks to Buy.
On July 9, 2026, Century Therapeutics, Inc. (NASDAQ:IPSC) announced that its abstracts were accepted for oral presentations at two upcoming scientific congresses
Both presentations will highlight CNTY-813, Century’s iPSC-derived islet replacement therapy program engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes. The presentations are scheduled for the 62nd Annual Meeting of the European Association for the Study of Diabetes, taking place September 28-October 2, 2026 in Milan, Italy, and the Breakthrough T1D Clinical & Research Congress 2026, taking place October 9-11, 2026 in Philadelphia, Pennsylvania. Century said CNTY-813 is designed to enable durable engraftment without chronic systemic immunosuppression, and the company is targeting an IND submission in the fourth quarter of 2026.
On June 9, Century Therapeutics announced new preclinical data for CNTY-813 at the American Diabetes Association Scientific Sessions. In preclinical models, the therapy demonstrated durable glucose control for over eight months and maintained insulin secretion under allogeneic immune pressure without immunosuppression. CEO Brent Pfeiffenberger said the data advance the company’s case for a “potentially functional cure” for type 1 diabetes, while noting that the IND submission remains on track for the fourth quarter of 2026 and initial clinical data are anticipated in the second half of 2027.